<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03219086</url>
  </required_header>
  <id_info>
    <org_study_id>ec nr 17/07/77</org_study_id>
    <nct_id>NCT03219086</nct_id>
  </id_info>
  <brief_title>Spinal Prilocaine for Caesarian Sections</brief_title>
  <official_title>A Prospective Randomized Double Blind Comparison of 7,5 mg Hyperbaric Bupivacaine With 2,5mcg Sufentanyl or 50 mg Hyperbaric Prilocaine With 2,5 mcg Sufentanyl for Caesarean Sections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Antwerp</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AZ Klina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AZ Monika</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AZ Middelheim</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Antwerp</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prilocaine theoretically could provide faster onset because of its lower pKa (7,7) compared
      to bupivacaine (8,1). The primary objective of this prospective double blind randomized trial
      is to determine block onset of spinal hyperbaric prilocaine compared to bupivacaine, both
      with a small dose of sufentanyl as an additive.The primary hypothesis is that a significant
      larger amount of patients will gain surgical readiness within 8 minutes after spinal
      injection of prilocaine with sufentanyl compared to bupivacaine with sufentanyl. Surgical
      readiness is defined as a sensory block level of T5 tested by loss of cold sensation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed as a randomised prospective double blind multi centre study.

      Following approval by the Hospital Ethics committee of the University Hospital Antwerp and
      all participating hospitals, all-in term (37-42 weeks of gestation) pregnant women planned
      for a caesarean section will be asked to participate in this trial.

      Patients will be randomised to receive either spinal prilocaine with sufentanyl or spinal
      bupivacaine with sufentanyl.The patient, the anaesthetist performing the CSE and the observer
      are not aware of the local anaesthetic solution administered.

      Preoperative a combined spinal epidural puncture will be performed in the sitting position at
      the level of L2-L3 or L3-L4 . Vital parameters will be registered at regular intervals. Block
      characteristics ( onset, duration and intensity of the sensory block and motor block) will be
      measured at regular intervals.

      Patients with insufficient analgesia will receive a top up dose of 5 ml lidocaine 2 % via the
      epidural catheter.

      Time of birth, neonatal outcome (Apgar score 1 min, 5 min and 10 minutes after birth) and
      admission to the nicu as well as umbilicus venous and arterial blood gasses are recorded.

      Patients will be discharged from the PACU when motor block reached a Bromage score 1 Time
      intervals of discharge to the ward will be registered.At the maternity ward the time of first
      contact of the baby and the mother and first breast feed (if applicable) will be registered.

      One week postoperative patients will be called and asked if they experienced any
      postoperative symptoms like headache, micturition problems or symptoms resembling Transient
      Neurological Symptoms
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2017</start_date>
  <completion_date type="Anticipated">August 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>prospective double blind randomised</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>The spinal solution will be prepared by an independent anaesthetist, anaesthetist trainee or research nurse on a sterile table after opening the sealed envelope with the appointed study group. The patient, the anaesthetist performing the CSE and the observer are not aware of the local anaesthetic solution administered.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>onset time surgical readiness</measure>
    <time_frame>from start spinal anaesthesia to start of surgery (up to 30 minutes)</time_frame>
    <description>amount of minutes from spinal injection (T0) to loss of cold sensation on the fifth thoracic dermatome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>regression interval of the motor block</measure>
    <time_frame>up to 3 hours</time_frame>
    <description>Time from spinal injection to a Bromage score of 1 (knee flexion possible)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>occurrence of hypotenstion</measure>
    <time_frame>from spinal injection(T0) to motor block regression ( up to 3 hours)</time_frame>
    <description>percentage of study group with hypotension defined as a systolic BP of less than 100 mm Hg or a 20% drop from the baseline level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sensory block level</measure>
    <time_frame>Up to 3 hours</time_frame>
    <description>highest dermatome measured during the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>discharge time maternity ward</measure>
    <time_frame>Up to 3 hours</time_frame>
    <description>the time interval from spinal injection (T0) to discharge to the maternity ward</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>First Breast feed</measure>
    <time_frame>up to 6 hours</time_frame>
    <description>the time interval from injection (T0) to first breast feeding</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Combined Spinal Epidural Anesthesia</condition>
  <condition>Prilocaine</condition>
  <condition>Bupivacaine</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Group M</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>combined spinal epidural anesthesia with spinal administration of 7,5 mg hyperbaric bupivacaine 0,5% (Marcaine H) + 2,5mcg sufentanyl ( 5 mcg/ml)( Janssens -cilag) +1 ml nacl0,9%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group P</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A combined spinal epidural anesthesia with spinal administration of 50 mg hyperbaric prilocaine 2% (Tachipri, Nordic Pharma) + 2,5mcg sufentanyl (5 mcg/ml) (Janssens-cilag)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>combined spinal epidural anaesthesia</intervention_name>
    <description>To give surgical anesthesia for performance of the caesarian section a combined spinal epidural anesthesia will be performed with different spinal solutions according to the appointed study group</description>
    <arm_group_label>Group M</arm_group_label>
    <arm_group_label>Group P</arm_group_label>
    <other_name>CSE</other_name>
    <other_name>Spinal anesthesia</other_name>
    <other_name>prilocaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prilocaine</intervention_name>
    <description>A combined spinal epidural anesthesia with spinal administration of 50 mg hyperbaric prilocaine 2% (Tachipri, Nordic Pharma) + 2,5mcg sufentanyl (5 mcg/ml) (Janssens-cilag)</description>
    <arm_group_label>Group P</arm_group_label>
    <other_name>tachipri</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>combined spinal epidural anesthesia with spinal administration of 7,5 mg hyperbaric bupivacaine 0,5% (Marcaine H) + 2,5mcg sufentanyl ( 5 mcg/ml)( Janssens -cilag) +1 ml nacl0,9%</description>
    <arm_group_label>Group M</arm_group_label>
    <other_name>marcaine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A term Pregnant women (37-42 weeks)scheduled for caesarian section

        Exclusion Criteria:

          -  Patient refusal

          -  Twin or multiple pregnancy

          -  Preeclampsia

          -  Contraindication neuraxial tecnique

          -  Indication general anaesthesia

          -  BMI before pregnancy &gt;35

          -  Maternal hight &lt;155 cm
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>AZ Middelheim</name>
      <address>
        <city>Berchem</city>
        <state>Antwerpen</state>
        <zip>2020</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eva Roofthooft, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ KLina</name>
      <address>
        <city>Brasschaat</city>
        <state>Antwerp</state>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David van Aken, MD</last_name>
      <phone>0032-3-6505110</phone>
      <email>David.Van.Aken@klina.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Monika</name>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peter Van De Putte, MD</last_name>
      <phone>0032/3/3206060</phone>
      <email>doktervdputte@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Antwerp</name>
      <address>
        <city>Antwerp</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Margaretha Breebaart, MD, PhD</last_name>
      <phone>003238213042</phone>
      <email>margaretha.breebaart@uza.be</email>
    </contact>
    <contact_backup>
      <last_name>veerle verheyen, nurse</last_name>
      <phone>003238214405</phone>
      <email>veerle.verheyen@uza.be</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 13, 2017</study_first_submitted>
  <study_first_submitted_qc>July 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2017</study_first_posted>
  <last_update_submitted>July 13, 2017</last_update_submitted>
  <last_update_submitted_qc>July 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Antwerp</investigator_affiliation>
    <investigator_full_name>Dr M. B. Breebaart</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>combined spinal epidural anesthesia</keyword>
  <keyword>caesarian section</keyword>
  <keyword>prilocaine</keyword>
  <keyword>bupivacaine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Sufentanil</mesh_term>
    <mesh_term>Prilocaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

